Form 4: Bristol-Myers Squibb Director Derica W. Rice Reports Acquisition of Deferred Share Units

Director Derica W. Rice reports acquiring deferred share units convertible to common stock in Bristol-Myers Squibb.

Summary

• On June 30, 2024, Derica W. Rice, a director of Bristol-Myers Squibb, reported the acquisition of 902.962 deferred share units.
• These units are convertible into shares of common stock upon settlement, which occurs when Rice ceases to be a director or at a previously specified future date.
• The price per share for the deferred share units is $41.53.
• Following the transaction, Rice beneficially owns 24,857.829 shares, including deferred compensation and reinvested dividends.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reflects a routine transaction by a company director. The acquisition of deferred share units can be seen as a positive sign, but it's not a major event.

Positives

• The acquisition of deferred share units by a director signals confidence in the company's future performance.

Future Outlook

The deferred share units will be converted into common stock upon settlement, which will occur when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge sentiment and potential future actions of key personnel.

Stakeholder Impact

• The acquisition of deferred share units by a director may have a minor positive impact on shareholder confidence.

Key Dates